Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine Hydrochloride for mCRPC
NCT07164794Phase 2Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of memantine in metastatic castration-resistant prostate cancer (mCRPC). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
memantine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07164794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164794.